文献速递血液净化与透析

抗菌光动力疗法用于维持性血液透析患者鼻腔去定植:一项先导性随机试验

Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients: A Pilot Randomized Trial.
PubMed 文献 · Am J Kidney Dis · 2022-11-14

该先导性随机试验纳入34例鼻腔携带金黄色葡萄球菌的维持性血液透析患者,比较单次抗菌光动力疗法与莫匹罗星局部方案的鼻腔去定植效果。治疗结束时,光动力疗法组71%与莫匹罗星组77%培养阴性(风险比0.92,95%CI 0.61-1.38,P=0.9);光动力疗法组无不良事件。

要点

  • 光动力疗法组17例全部依从,莫匹罗星组17例中13例(77%)依从。
  • 治疗结束时培养阴性率光动力疗法组71% vs 莫匹罗星组77%,风险比0.92(95%CI 0.61-1.38,P=0.9)。
  • 光动力疗法组培养转阴者中67%在3个月内再定植。

核心结论

  • 光动力疗法是治疗鼻腔金黄色葡萄球菌携带的一种可行方法,未来需开展更大规模研究以确定其是否与莫匹罗星标准治疗等效。

研究设计与样本

  • 随机对照先导性研究,纳入34例鼻腔携带金黄色葡萄球菌的维持性血液透析患者。
  • 随机分配至单次抗菌光动力疗法(波长660nm,400mW/cm2,300秒,亚甲蓝0.01%)或莫匹罗星局部方案(每日两次,共5天)。

主要发现

  • 光动力疗法组17例全部依从,莫匹罗星组17例中13例(77%)依从。
  • 治疗结束时,光动力疗法组12例(71%)与莫匹罗星组13例(77%)培养阴性,风险比0.92(95%CI 0.61-1.38,P=0.9)。
  • 光动力疗法组治疗结束时培养阴性的患者中,67%在3个月内再定植。
  • 光动力疗法组无不良事件。

局限性

  • 检测仅限于评估鼻腔定植,未评估感染并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Infections are an important cause of mortality among patients receiving maintenance hemodialysis. Staphylococcus aureus is a frequent etiological agent, and previous nasal colonization is a risk factor for infection. Repeated antimicrobial decolonization reduces infection in this population but can induce antibiotic resistance. We compared photodynamic therapy, a promising bactericidal treatment that does not induce resistance, to mupirocin treatment among nasal carriers of S aureus. STUDY DESIGN: Randomized controlled pilot study. SETTING & PARTICIPANTS: 34 patients receiving maintenance hemodialysis who had nasal carriage of S aureus. INTERVENTIONS: Patients were randomly assigned to decolonization with a single application of photodynamic therapy (wavelength of 660nm, 400mW/cm2, 300 seconds, methylene blue 0.01%) or with a topical mupirocin regimen (twice a day for 5 days). OUTCOME: Nasal swabs were collected at time 0 (when the carrier state was identified), directly after treatment completion, 1 month after treatment, and 3 months after treatment. Bacterial isolates were subjected to proteomic analysis to identify the species present, and antimicrobial susceptibility was characterized. RESULTS: All 17 participants randomized to photodynamic therapy and 13 of 17 (77%) randomized to mupirocin were adherent to treatment. Directly after treatment was completed, 12 participants receiving photodynamic therapy (71%) and 13 participants treated with mupirocin (77%) had cultures that were negative for S aureus (risk ratio, 0.92 [95% CI, 0.61-1.38]; P=0.9). Of the patients who had negative cultures directly after completion of photodynamic therapy, 67% were recolonized within 3 months. There were no adverse events in the photodynamic therapy group. LIMITATIONS: Testing was restricted to assessing nasal colonization; infectious complications were not assessed. CONCLUSIONS: Photodynamic therapy is a feasible approach to treating nasal carriage of S aureus. Future larger studies should be conducted to determine whether photodynamic therapy is equivalent to the standard of care with mupirocin. FUNDING: Government grant (National Council for Scientific and Technological Development process 3146682020-9). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04047914.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Bezerra DT, La Selva A, Cecatto RB, et al. Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients: A Pilot Randomized Trial. Am J Kidney Dis. 2022. PMID: 36396084. doi:10.1053/j.ajkd.2022.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。